Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia's collaboration with Paris Hospital District moves forward

Aiforia Technologies

Translation: Original comment published in Finnish on 9/5/2024 at 12:13 noon EEST.

The start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release, the collaboration at this stage includes the use of Aiforia's AI solutions in the analysis of tissue samples from prostate cancer patients and the use of Aiforia's AI model development software. Aiforia will be deployed at the pathology department of the Bicetre Hospital (AP-HP Paris Saclay University), which has been a pilot site for digital pathology in France since 2018.

The clinical use of Aiforia in Paris will start on a somewhat smaller scale (1/5 of the current CE-marked AI models), so revenue streams from the customer are expected to be slow. The contract partner, Assistance Publique–Hôpitaux de Paris (AP-HP), is a university hospital group with 38 hospitals in the Paris region, serving 8 million patients per year. Thus, the potential for expansion in this hospital group alone is significant. In addition, Aiforia will be able to demonstrate its product capabilities directly at the heart of the digitization of French pathology and is well positioned to take a significant market share in France, making the collaboration strategically valuable in the longer term. Our forecasts have already included this account and require Aiforia to continue to deliver new customer wins and customer deployment progress, so the release has no impact on our forecasts or our view of the company.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures2024-08-29

202324e25e
Revenue2.43.45.8
growth-%49.3 %41.2 %71.1 %
EBIT (adj.)-12.9-12.1-11.8
EBIT-% (adj.)-537.1 %-358.4 %-204.4 %
EPS (adj.)-0.50-0.42-0.41
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Answering myself: The volume at Fimlab was approx. 1,600 slides in September 2025 and 3,500 in October, and the volume is growing. Price per...
19 minutes ago
by Jekkku
3
Imaging in this context refers to radiology, so the ambiguity you mentioned does not exist. Aiforia’s solutions are for clinical pathology and...
34 minutes ago
by Nikkoton
2
That pathology field covers a lot of ground, and I suppose it’s about interpreting all kinds of samples digitally using AI, whether we’re talking...
1 hour ago
by Salvelinus
0
Of course, it’s worth remembering here that Aiforia’s solution is for pathology and not for imaging.
1 hour ago
by Nikkoton
1
I’ve been checking the Siemens Healthineers website to see if there are any mentions. It seems like there are big medical events happening right...
1 hour ago
by Salvelinus
1
Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a...
13 hours ago
by Verneri Pulkkinen
25
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and...
15 hours ago
by Opa
16
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.